参考文献/References:
[1] SIEGEL R L,MILLER K D,JEMAL A.Cancerstatistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
[2] SALMANINEJAD A,VALILOU S F,SHABGAH A G,et al.PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy[J].J Cell Physiol,2019,234(10):16824-16837.
[3] JUNQUEIRA ALVES C,YOTOKO K,ZOU H,et al.Origin and evolution of plexins,semaphorins,and Met receptor tyrosine kinases[J].Sci Rep,2019,9(1):1970.
[4] LUEBECK G E,VAUGHAN T L,CURTIUS K,et al.Modeling historic incidence trends implies early field cancerization in esophageal squamous cell carcinoma[J].PLoS Comput Biol,2021,17(5):e1008961.
[5] QING,LIAN J,YUE D,et al.Musashil,a potential prognostic marker in esophageal squamous cell carcinoma[J].Oncol Rep,2017,38(3):1724-1732.
[6] 韩潇,黄莉,李文婷,等.PD-1和PD-L1在Ⅳa期鼻咽癌组织中的表达及临床意义[J].中华放射肿瘤学杂志,2017,26(10):1131-1136.
[7] HAYMAKER C,JOHNSON D H,MURTHY R,et al.Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma[J].Cancer Discov,2021,published online ahead of print.DOI:10.1158/2159-8290.CD-20-1546.
[8] SHI T,ZHU S,GUO H,et al.The impact of programmed death-ligand 1 expression on the prognosis of early stage resected non-small cell lung cancer: a meta-analysis of literatures[J].Front Oncol,2021,11:567978.
[9] FRANZOLING,TAMAGNONEL.Semaphorin signaling in cancer-associated inflammation[J].Int J Mol Sci,2019,20(2):377.
[10] WYLIE T,GARG R,RIDLEY A J,et al.Analysis of the interaction of Plexin-B1 and Plexin-B2 with Rnd family proteins[J].PLoS One,2017,12(10):e0185899.
[11] 周海萍,沈忠磊.胰腺癌组织中Plexin-B1、Gli1蛋白表达及其与临床特征的关系[J].浙江医学,2018,40(9):937-939,972.
[12] 王维军,杨华.神经丛素A1在人脑胶质瘤中的表达与意义[J].中国微侵袭神经外科杂志,2015,20(3):134-135.
[13] 高锋,钱文霞,冯一中.非小细胞肺癌中TIM-3、PD-1、PD-L1的表达与临床意义[J].海南医学,2019,30(2):154-158.
[14] 闫风彩,金木兰,石峰,等.PD-1/PD-L1在恶性肿瘤中的表达及研究进展[J].诊断病理学杂志,2019,26(1):61-65.